Morris J Brown

List of Publications by Year in Descending Order

76 papers	7,304 citations	31 h-index	81 g-index
81 ext. papers	9,374 ext. citations	15.2 avg, IF	5.07 L-index

#	Paper	IF	Citations
76	The power of genetic diversity in genome-wide association studies of lipids. *Nature*, **2021**,	50.4	24
75	CTNNB1-Mutant Aldosterone-Producing Adenomas With Somatic Mutations of GNA11/GNAQ Have Distinct Phenotype and Genotype. *Journal of the Endocrine Society*, **2021**, 5, A65-A66	0.4	78
74	Development of [F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. *Journal of Medicinal Chemistry*, **2021**, 64, 9321-9329	8.3	3
73	CONNed in Pregnancy. *Hypertension*, **2021**, 78, 241-249	8.5	1
72	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. *Nature Genetics*, **2021**, 53, 1360-1372	36.3	9
71	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *New England Journal of Medicine*, **2021**, 385, 1147	59.2	16
70	Chronotherapy in hypertension: the devil is in the details. *European Heart Journal*, **2020**, 41, 1606-1607	9.5	11
69	ANO4 (Anoctamin 4) Is a Novel Marker of Zona Glomerulosa That Regulates Stimulated Aldosterone Secretion. *Hypertension*, **2019**, 74, 1152-1159	8.5	7
68	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. *Nature Genetics*, **2019**, 51, 636-648	36.3	59
67	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 464-475	18.1	126
66	Investigation of primary aldosteronism in patients with resistant hypertension - Authors' reply. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 600-601	18.1	3
65	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. *PLoS ONE*, **2018**, 13, e0198166	3.7	31
64	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nature Genetics*, **2018**, 50, 1412-1425	36.3	386
63	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nature Genetics*, **2017**, 49, 403-415	36.3	313
62	NEFM (Neurofilament Medium) Polypeptide, a Marker for Zona Glomerulosa Cells in Human Adrenal, Inhibits D1R (Dopamine D1 Receptor)-Mediated Secretion of Aldosterone. *Hypertension*, **2017**, 70, 357-364	8.5	10
61	Exome-wide association study of plasma lipids in >300,000 individuals. *Nature Genetics*, **2017**, 49, 1758-1766	36.3	310
60	Novel Mechanism for Buffering Dietary Salt in Humans: Effects of Salt Loading on Skin Sodium, Vascular Endothelial Growth Factor C, and Blood Pressure. *Hypertension*, **2017**, 70, 930-937	8.5	40

59	Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. *Hypertension*, **2017**,	8.5	85
58	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. *Journal of the American Heart Association*, **2017**, 6,	6	57
57	Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). *Hypertension*, **2017**, 69, 189-196	8.5	23
56	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nature Genetics*, **2016**, 48, 1151-1161	36.3	181
55	Transcriptome Pathway Analysis of Pathological and Physiological Aldosterone-Producing Human Tissues. *Hypertension*, **2016**, 68, 1424-1431	8.5	22
54	Regulation of aldosterone secretion by Cav1.3. *Scientific Reports*, **2016**, 6, 24697	4.9	24
53	Telling Tails: Very High Plasma Renin Levels Prompt the Diagnosis of Renal Artery Stenosis, Despite Initial Negative Imaging. *Hypertension*, **2016**, 68, 11-6	8.5	5
52	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 136-47	18.1	72
51	Primary aldosteronism as a public health issue - Authors' reply. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 973-974	18.1	1
50	Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations. *New England Journal of Medicine*, **2016**, 374, 1494	59.2	15
49	Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 805-7	18.1	5
48	Role of ANO4 in regulation of aldosterone secretion in the zona glomerulosa of the human adrenal gland. *Lancet, The*, **2015**, 385 Suppl 1, S62	40	8
47	Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?. *Trials*, **2015**, 16, 80	2.8	24
46	LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E836-44	5.6	20
45	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. *BMJ Open*, **2015**, 5, e008951	3	12
44	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet, The*, **2015**, 386, 2059-2068	40	632
43	Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations. *New England Journal of Medicine*, **2015**, 373, 1429-36	59.2	98
42	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial. *BMJ Open*, **2015**, 5, e007645	3	8

41	Primary Aldosteronism: the spectre of cure. *Clinical Endocrinology*, **2015**, 82, 785-8	3.4	3
40	DACH1, a zona glomerulosa selective gene in the human adrenal, activates transforming growth factor-β signaling and suppresses aldosterone secretion. *Hypertension*, **2015**, 65, 1103-10	8.5	19
39	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. *BMJ Open*, **2015**, 5, e008086	3	5
38	New genetic loci link adipose and insulin biology to body fat distribution. *Nature*, **2015**, 518, 187-196	50.4	920
37	Ins and outs of aldosterone-producing adenomas of the adrenal: from channelopathy to common curable cause of hypertension. *Hypertension*, **2014**, 63, 24-6	8.5	8
36	Defining the role of common variation in the genomic and biological architecture of adult human height. *Nature Genetics*, **2014**, 46, 1173-86	36.3	1339
35	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nature Genetics*, **2014**, 46, 826-36	36.3	199
34	Clinical value of plasma renin estimation in the management of hypertension. *American Journal of Hypertension*, **2014**, 27, 1013-6	2.3	4
33	Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. *American Journal of Human Genetics*, **2014**, 94, 349-60	11	131
32	Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. *Nature Genetics*, **2013**, 45, 1055-60	36.3	353
31	Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E819-29	5.6	144
30	Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 100-9	5.6	150
29	Platt versus Pickering: what molecular insight to primary hyperaldosteronism tells us about hypertension. *JRSM Cardiovascular Disease*, **2012**, 1,	1.1	1
28	Navigating the shoals in hypertension: discovery and guidance. *BMJ, The*, **2012**, 344, d8218	5.9	14
27	Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. *Lancet, The*, **2011**, 377, 312-20	40	123
26	The choice of diuretic in hypertension: saving the baby from the bathwater. *Heart*, **2011**, 97, 1547-51	5.1	6
25	Heterogeneity of blood pressure response to therapy. *American Journal of Hypertension*, **2010**, 23, 926-8	2.3	12
24	Success and failure of vaccines against renin-angiotensin system components. *Nature Reviews Cardiology*, **2009**, 6, 639-47	14.8	22

23	Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. *British Journal of Clinical Pharmacology*, **2008**, 65, 646-52	3.8	9
22	Therapeutic potential of vaccines in the management of hypertension. *Drugs*, **2008**, 68, 2557-60	12.1	8
21	Response to Letter Regarding Article, The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio *Circulation*, **2008**, 117,	16.7	1
20	Renin: friend or foe?. *Heart*, **2007**, 93, 1026-33	5.1	53
19	Hypertension and ethnic group. *BMJ, The*, **2006**, 332, 833-6	5.9	94
18	AT2 receptor stimulation may halt progression of pheochromocytoma. *Annals of the New York Academy of Sciences*, **2006**, 1073, 436-43	6.5	4
17	Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. *Clinical Science*, **2004**, 107, 167-73	6.5	86
16	A rational basis for selection among drugs of the same class. *British Heart Journal*, **2003**, 89, 687-94		7
15	A genome-wide search for susceptibility loci to human essential hypertension. *Hypertension*, **2000**, 35, 1291-6	8.5	73
14	Pathoaetiology, epidemiology and diagnosis of hypertension. *Drugs*, **2000**, 59 Suppl 2, 1-12; discussion 39-40	12.1	31
13	Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. *Hypertension*, **1999**, 34, 8-14	8.5	121
12	Selective beta1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium. *British Journal of Pharmacology*, **1999**, 128, 135-41	8.6	7
11	Optimisation of antihypertensive treatment by crossover rotation of four major classes. *Lancet, The* , **1999**, 353, 2008-13	40	273
10	Who manages hypertensive patients? The primary care-hospital interface. *American Journal of Hypertension*, **1998**, 11, 740-3	2.3	
9	The causes of essential hypertension. *British Journal of Clinical Pharmacology*, **1996**, 42, 21-7	3.8	24
8	Blood pressure and the M235T polymorphism of the angiotensinogen gene. *Hypertension*, **1996**, 28, 907-11	8.5	47
7	Expression of the alpha- and beta-subunits of the stimulatory and inhibitory G-proteins in beta 1-adrenoceptor-blocked and non-beta-adrenoceptor-blocked human atrium. *Clinical Science*, **1995**, 88, 571-80	6.5	6
6	Differences in transcription and translation of long and short Gs alpha, the stimulatory G-protein, in human atrium. *Clinical Science*, **1995**, 89, 487-95	6.5	8

5	A 5-hydroxytryptamine receptor in human atrium. *British Journal of Pharmacology*, **1990**, 100, 879-85	8.6	154
4	Binding sites for 125I-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography. *Clinical Science*, **1989**, 77, 129-31	6.5	45
3	Adrenaline and alpha 2-adrenoceptors in hypertension. *Basic and Clinical Pharmacology and Toxicology*, **1988**, 63 Suppl 1, 16-20		1
2	Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man. *Clinical Science*, **1988**, 74, 359-63	6.5	36
1	A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig in vitro. *British Journal of Pharmacology*, **1987**, 91, 687-91	8.6	22